» Articles » PMID: 33707976

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Overview
Publisher Dove Medical Press
Specialty Public Health
Date 2021 Mar 12
PMID 33707976
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for their promising antidepressant, anxiolytic, and anti-addictive effects. Considering this evidence, this article aims to explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems. As a main benefit, these substances produce rapid and enduring effects with the administration of single or few doses, which could lead to new treatment possibilities for patients with severe mental disorders resistant to the usual medications. The main challenge is associated with the fact that these substances remain scheduled in most countries and are associated with social stigma related to their recreational use (especially LSD and psilocybin). This situation makes it exceedingly difficult to conduct clinical trials, although international conventions allow such research. Ethically, this could be interpreted as a violation of human rights since thousands of people are prevented from having access to possible benefits. Interestingly, ritual ayahuasca use is more acceptable to the public than the use of psilocybin-containing mushrooms or LSD. The controlled, clinical use of LSD and psilocybin seems to be less criticized and is being explored by the industry. Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years. Which highlights the need for an urgent dialogue between science, health system, society, and politics.

Citing Articles

The Psych Behind Psychedelics: Exploring Hallucinogen Use as a Marker for Untreated Mental Health Disorders.

Ahmed L, Konda S, Ganti L Health Psychol Res. 2025; 13():127794.

PMID: 39790101 PMC: 11710884. DOI: 10.52965/001c.127794.


Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.

Mian M, Dinh M, Coker A, Mitchell J, Anderson B Am J Psychiatry. 2025; 182(1):6-9.

PMID: 39741445 PMC: 11772052. DOI: 10.1176/appi.ajp.20230787.


Substance Use and Mental Health in Emerging Adult University Students Before, During, and After the COVID-19 Pandemic in Mexico: A Comparative Study.

Hernandez-Fuentes G, Romero-Michel J, Guzman-Sandoval V, Diaz-Martinez J, Delgado-Enciso O, Garcia-Perez R Diseases. 2024; 12(12.

PMID: 39727633 PMC: 11727221. DOI: 10.3390/diseases12120303.


Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Wang E, Mathai D, Gukasyan N, Nayak S, Garcia-Romeu A Sci Rep. 2024; 14(1):28022.

PMID: 39543323 PMC: 11564663. DOI: 10.1038/s41598-024-78736-1.


Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F CNS Drugs. 2024; 38(10):771-789.

PMID: 39033264 DOI: 10.1007/s40263-024-01101-3.


References
1.
Bouso J, Sanchez-Aviles C . Traditional Healing Practices Involving Psychoactive Plants and the Global Mental Health Agenda: Opportunities, Pitfalls, and Challenges in the "Right to Science" Framework. Health Hum Rights. 2020; 22(1):145-150. PMC: 7348435. View

2.
Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H . DMT Models the Near-Death Experience. Front Psychol. 2018; 9:1424. PMC: 6107838. DOI: 10.3389/fpsyg.2018.01424. View

3.
de la Torre R, Farre M, Roset P, Pizarro N, Abanades S, Segura M . Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004; 26(2):137-44. DOI: 10.1097/00007691-200404000-00009. View

4.
de Almeida R, de Menezes Galvao A, da Silva F, Silva E, Palhano-Fontes F, Maia-de-Oliveira J . Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. Front Psychol. 2019; 10:1234. PMC: 6558429. DOI: 10.3389/fpsyg.2019.01234. View

5.
Galvao-Coelho N, de Menezes Galvao A, de Almeida R, Palhano-Fontes F, Campos Braga I, Soares B . Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020; 34(10):1125-1133. DOI: 10.1177/0269881120936486. View